Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 13 Results

Title
Intervention Indication Therapeutic Area Year Actions
Axicabtagene ciloleucel for relapsed/refractory diffuse large B-cell lymphoma – second-line Axicabtagene Ciloleucel (Yescarta; KTE-C19) Diffuse large B-cell lymphoma (DLBCL) Haematological Cancer and Lymphomas 2019 View  |  Download
Epcoritamab for diffuse large B-cell lymphoma after two previous treatments Epcoritamab (GEN-3013) Diffuse large B-cell lymphoma (DLBCL) Haematological Cancer and Lymphomas 2021 View  |  Download
Glofitamab for relapsed or refractory diffuse large B-cell lymphoma Glofitamab (RG-6026) Diffuse large B-cell lymphoma (DLBCL) , High grade B cell lymphoma (HGBCL) , Primary mediastinal large B-cell lymphoma (PMBCL) Haematological Cancer and Lymphomas 2021 View  |  Download
Glofitamab with gemcitabine, oxaliplatin and rituximab for treating relapsed or refractory diffuse large B-cell lymphoma Gemcitabine (Gemzar; gemcitabine hydrochloride) , Glofitamab (RG-6026) , Oxaliplatin , Rituximab (MabThera; Rituxan; RG 105) Diffuse large B-cell lymphoma (DLBCL) Haematological Cancer and Lymphomas 2022 View  |  Download
Lenalidomide in addition to R-CHOP chemotherapy for diffuse large B-cell lymphoma Lenalidomide (Revlimid) , R-CHOP Diffuse large B-cell lymphoma (DLBCL) Haematological Cancer and Lymphomas 2019 View  |  Download
Lisocabtagene Maraleucel (Liso-Cel) for Relapsed/Refractory Diffuse Large B-cell Lymphoma Lisocabtagene maraleucel (Liso-cel; JCAR017) Diffuse large B-cell lymphoma (DLBCL) Haematological Cancer and Lymphomas 2018 View  |  Download
Lisocabtagene maraleucel for transplant-eligible and ineligible, relapsed or refractory, aggressive B-cell non-Hodgkin lymphoma - second-line Lisocabtagene maraleucel (Liso-cel; JCAR017) Diffuse large B-cell lymphoma (DLBCL) , Follicular lymphoma , Non-Hodgkin lymphoma (NHL) , Primary mediastinal large B-cell lymphoma (PMBCL) Haematological Cancer and Lymphomas 2020 View  |  Download
Loncastuximab Tesirine for relapsed or refractory diffuse large B-cell lymphoma – third line Loncastuximab Tesirine (ADCT-402; Lonca; Zylonta) Diffuse large B-cell lymphoma (DLBCL) Haematological Cancer and Lymphomas 2021 View  |  Download
Polatuzumab vedotin in addition to R-CHP for diffuse large B-cell lymphoma – first line Chemotherapy , Polatuzumab vedotin (DCDS4501A; RG7596; RG-7596; Polivy) Diffuse large B-cell lymphoma (DLBCL) Haematological Cancer and Lymphomas 2020 View  |  Download
Polatuzumab vedotin in combination with rituximab and bendamustine for the treatment of diffuse large B-cell lymphoma Bendamustine (Treanda; EP-3102; Levact; Ribomustin; bendamustine hydrochloride monohydrate; bendamustine hydrochloride) , Polatuzumab vedotin (DCDS4501A; RG7596; RG-7596; Polivy) , Rituximab (MabThera; Rituxan; RG 105) Diffuse large B-cell lymphoma (DLBCL) Haematological Cancer and Lymphomas 2018 View  |  Download
1 2
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications